• Interpace Biosciences set a 1-for-5 reverse stock split effective Aug. 27 to support a proposed Nasdaq uplisting.
• Shares to trade split-adjusted on OTCID at the open Aug. 27; ticker to switch temporarily to IDXGD for 20 sessions.
• Outstanding shares to drop to about 5,500,000 from about 27,700,000; authorized share count unchanged.
• Nasdaq bid-price compliance is the primary goal; additional listing hurdles remain, including a $15 million public float threshold.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Interpace Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-040329), on August 27, 2026, and is solely responsible for the information contained therein.